Over 12 months, Medifast Inc saw more buying than selling from its insiders — purchases of about $1.7 million against sales of $226,000.
Kiai Parsa (Director) made the biggest buy, worth around $515,000. That includes C-suite money, which tends to get the most attention.
Big money check: 113 institutions held MED as of Q2 2026, and more funds bought than sold. Quarter by quarter: 3 quarters in a row of net buying by insiders. Insiders bought in 4 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Chard Daniel R | Director | Sell | 9,544 | $11.73 | $112K | SEC |
| Sep 30, 2026 | Chard Daniel R | Director | Sell | 9,545 | $11.98 | $114K | SEC |
| Aug 28, 2026 | Kiai Parsa | Director | Buy | 41,975 | $12.26 | $515K | SEC |
| Aug 28, 2026 | Kiai Parsa | Director | Buy | 1,175 | $12.26 | $14K | SEC |
| Aug 26, 2026 | Kiai Parsa | Director | Buy | 4,211 | $12.00 | $51K | SEC |
| Aug 26, 2026 | Kiai Parsa | Director | Buy | 118 | $12.00 | $1K | SEC |
| Aug 21, 2026 | Kiai Parsa | Director | Buy | 41,975 | $11.60 | $487K | SEC |
| Aug 21, 2026 | Kiai Parsa | Director | Buy | 799 | $11.66 | $9K | SEC |
| Aug 21, 2026 | Kiai Parsa | Director | Buy | 28,538 | $11.66 | $333K | SEC |
| Aug 21, 2026 | Kiai Parsa | Director | Buy | 1,175 | $11.60 | $14K | SEC |
| May 12, 2026 | SCHLACKMAN SCOTT | Director | Buy | 2,500 | $12.65 | $32K | SEC |
| May 12, 2026 | SCHLACKMAN SCOTT | Director | Buy | 2,500 | $12.53 | $31K | SEC |
| Mar 27, 2026 | Chard Daniel R | CEO | Buy | 17,678 | $10.11 | $179K | SEC |
| Jun 17, 2025 | Chard Daniel R | CEO | Buy | 381 | $13.13 | $5K | SEC |
| Mar 12, 2024 | SCHLACKMAN SCOTT | Director | Sell | 1,300 | $39.41 | $51K | SEC |
In the last 12 months Medifast Inc insiders made open-market purchases worth about $1.7 million and sales worth about $226,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MED was filed on 2026-09-30.
113 investment managers reported holding MED in SEC Form 13F filings for Q2 2026.
No congressional trades in MED were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).